[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613178":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":41,"collaborators":10,"id":43,"slug":10,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"HCM",null,"diagnosed with hypertrophic cardiomyopathy by echocardiography and cardiac magnetic resonance imaging",{"label":13,"type":10,"description":14,"interventionNames":10},"phenocopy","patients with left-ventricular hypertrophy attributable to non-hypertrophic cardiomyopathy conditions",{"label":16,"type":10,"description":17,"interventionNames":10},"normal control","healthy individuals without myocardial hypertrophy",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Xiaojie Xie, MD, PhD","CONTACT","(+86)0571-87784700","xiexj@zju.edu.cn",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Second Affiliated Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310009","China","CN",{"type":34,"coordinates":35},"Point",[36,37],120.16142,30.29365,{"lat":37,"lon":36},[40],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100613178",false,"NCT07263204","AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy","Precision Diagnosis and Prognostic Prediction of Hypertrophic Cardiomyopathy Using Artificial Intelligence: A Multicenter Study","Inclusion Criteria:\n\n1. Adults aged ≥ 18 years.\n2. HCM cohort: Adults diagnosed with hypertrophic cardiomyopathy in accordance with the \\*2023 Chinese Guidelines for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy in Adults\\*.\n3. HCM phenocopy cohort: Adults with an LV wall thickness ≥ 13 mm at any site on echocardiography.\n4. Healthy-control cohort: Adults with no history of cardiac disease and no evidence of myocardial hypertrophy on echocardiography.\n\nExclusion Criteria:\n\nPatients from whom analyzable ECG data cannot be obtained.",true,"ALL","18 Years",{"count":53,"type":54},15000,"ESTIMATED","OBSERVATIONAL","By harnessing artificial intelligence to decode the 12-lead electrocardiogram, the project will enable precise ECG-based phenotyping of hypertrophic cardiomyopathy-accurately classifying septal, apical, and other morphologic subtypes-while simultaneously differentiating HCM from hypertensive heart disease, aortic stenosis, and other phenocopy disorders.",[58,59],"Hypertrophic Cardiomyopathy (HCM)","Left Ventricular Hypertrophy","2025-11-23",{"date":62,"type":63},"2025-12-04","ACTUAL",{"date":65,"type":63},"2025-01-01",{"date":67,"type":54},"2026-12-31",{"name":5,"class":6},1]